Toxicity Clinical Trial
Official title:
Phase II Study on Volume De-escalation in Neoadjuvant Radiochemotherapy of Rectal Cancer
The study outlines a clinical prospective protocol consisting of preoperative chemoradiation in locally advanced rectal cancer, without elective pelvic nodal irradiation. The proposal to exclude lateral spaces from the target volume is based on the assumption that the radiological evidence of recurrence in the lateral lymph nodes is shown to be below 5%. In the study all patients underwent an accurate pre-treatment work-up including total body CT, pelvic MRI and 18-fluorodeoxyglucose PET/CT, in order to include patients without evidence of disease in lateral lymph nodes. The primary endpoint of the study was the reduction of gastrointestinal toxicity; secondary endpoints were the pathological complete response (pCR), the local control (LC) rate, the overall survival (OS) and the disease-free survival (DFS).
Patients affected by histologically proven rectal cancer were considered for enrollment in a prospective protocol that included preoperative CRT and surgical treatment. All patients underwent pre-treatment work-up (clinical examination, pancolonoscopy with biopsy, total body CT scan, pelvic MRI, and whole body 18-fluorodeoxyglucose PET/CT scan). Eligible patients had primary resectable cT2-low lying-T3, N0-N1 adenocarcinoma of the rectum, without evidence of disease in lateral lymph nodes. Additional eligibility criteria included performance status as well as liver, kidney, and bone marrow function that allowed for long-course CRT, older than 18 years, and no distant metastases. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02273713 -
The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)
|
Phase 1/Phase 2 | |
Terminated |
NCT00531076 -
Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02397434 -
Adjuvant Radiotherapy After Cystectomy for Muscle Invasive Bladder Cancer
|
N/A | |
Withdrawn |
NCT03342300 -
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT02649491 -
Using an Electronic Nose to Predict Gastrointestinal Consequences of Pelvic Radiotherapy
|
N/A | |
Terminated |
NCT00618917 -
MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02760823 -
Alpha Lipoic Acid as an Adjuvant Treatment in Acute Phosphide Poisoning
|
Phase 2 | |
Completed |
NCT02864030 -
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
|
Phase 4 | |
Completed |
NCT00890448 -
Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate
|
N/A | |
Terminated |
NCT01760356 -
Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients
|
||
Recruiting |
NCT06044623 -
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
|
Phase 3 | |
Completed |
NCT01091766 -
Sensitivity of ECG on Detection of Three Different Intravascular Applied Test Doses of Bupivacaine and Epinephrine
|
Phase 4 | |
Completed |
NCT05277480 -
Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)
|
Phase 2 | |
Recruiting |
NCT03978949 -
Prevention of Radiotherapy Induced Enteropathy by Probiotics (PREP)
|
Phase 3 | |
Completed |
NCT03491371 -
Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use
|
N/A | |
Completed |
NCT02143219 -
Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT02054741 -
Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer
|
N/A | |
Not yet recruiting |
NCT06087718 -
Feasibility of the Maastro Applicator in Rectal Cancer
|
N/A | |
Terminated |
NCT02512809 -
Isoflurane-induced Neuroinflammation in Children With Hydrocephalus
|
Phase 3 | |
Completed |
NCT03612544 -
The ESTxENDS Trial- Substudy on the Effect on Toxins From Using Electronic Nicotine Delivery Systems (ENDS/Vaporizer/E-cig)
|
N/A |